Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction

Trial Profile

Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Danicamtiv (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Adverse reactions; Proof of concept
  • Sponsors MyoKardia
  • Most Recent Events

    • 22 Jun 2020 According to a MyoKardia media release, the company will host a conference call and webcast for investors and analysts today to review the data from this study and to discuss future development plans for danicamtiv in targeted groups of patients with systolic disease.
    • 22 Jun 2020 According to a MyoKardia media release, positive phase 2a results were published in the European Journal of Heart Failure.
    • 22 Jun 2020 According to a MyoKardia media release, positive phase 2a results were featured in a Late-Breaking Science Session during the HFA Discoveries online event from the Heart Failure Association of the European Society of Cardiology (ESC).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top